BioSpace News Archive

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today announced that management will participate in a panel at the H.C. Wainwright 3rd Annual NASH Investor Conference, taking place October 21, 2019 in New York City.

AVID200 is a first-in-class, selective inhibitor of TGF-beta 1 & 3, the main pathogenic TGF-beta isoforms; AVID200 spares TGF-beta 2 for optimal safety

Technavio has been monitoring the global HIV therapeutics market since 2016 and the market is poised to grow by USD 2.44 billion during 2019-2023, progressing at a CAGR of almost 2% during the forecast period.

Medline and the Medline Foundation today awarded eight nonprofit organizations with grants to increase awareness, early detection, prevention and/or treatment of breast cancer through Medline’s Community Impact Grant Program for Breast Cancer Awareness.

Biologica Technologies, developers and marketers of ProteiOS®, announced today that they have been recognized as one of the Top 10 MedTech Startups in 2019 by MedTech Outlook Magazine.

Educational highlights of the Nov. 7-8 event include disaster response and Stop the Bleed

Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

HCSC coverage decision adds more than 16 million covered lives for Eversense CGM

The product is manufactured at Akorn’s Amityville, New York manufacturing facility.

Investment to support scaling of technology platform and advance multiple biotech partnerships